Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
203 hedge funds and large institutions have $2.22B invested in Dicerna Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 62 increasing their positions, 64 reducing their positions, and 25 closing their positions.
80% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 25
38% more capital invested
Capital invested by funds: $1.61B → $2.22B (+$612M)
31% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $8.22M
11% more funds holding
Funds holding: 183 → 203 (+20)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
3% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$17M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$14M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$13.9M |
| 4 |
JP Morgan Chase
New York
|
+$12.2M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$31.3M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$30.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$23.8M |
| 4 |
BM
Bridger Management
New York
|
-$15.1M |
| 5 |
Goldman Sachs
New York
|
-$14M |
DRNA Hedge Fund Activity: Q2 2021 in Review
203 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2021, worth a combined $2.22B — up 38% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new DRNA positions and 25 closed out — a net gain of 20 holders — while 62 added to existing stakes and 64 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $17M. The largest seller was Wellington Management Group, cutting an estimated $31.3M.
- 203 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2021, up from 183 in Q1 2021.
- Funds reported $2.22B of Dicerna Pharmaceuticals, Inc. stock for Q2 2021, up 38% quarter-over-quarter.
- 45 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2021 and 25 closed out, a net change of +20 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2021 was Assenagon Asset Management, an estimated $17M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2021 was Wellington Management Group, an estimated $31.3M sold.
Based on aggregated 13F filings for Q2 2021.